<DOC>
	<DOCNO>NCT02787785</DOCNO>
	<brief_summary>The MADIT S-ICD trial design evaluate subject prior myocardial infarction , diabetes mellitus relatively preserved ejection fraction 36-50 % survival benefit receive subcutaneous implantable cardioverter defibrillator ( S-ICD ) compare receive conventional medical therapy .</brief_summary>
	<brief_title>Multicenter Automatic Defibrillator Implantation Trial With Subcutaneous Implantable Cardioverter Defibrillator</brief_title>
	<detailed_description>In study , subject randomize receive subcutaneous implantable cardioverter defibrillator Conventional Medical Therapy ( CMT ) . Randomization stratify enrol site , 2:1 ( S-ICD : CMT ) scheme . Length follow-up subject dependent date entry study , since subject follow common study termination date .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Tachycardia</mesh_term>
	<criteria>Age â‰¥ 65 year date consent Diabetes mellitus treated oral hypoglycemic agent , noninsulin injectable and/or insulin past 3 calendar month longer prior consent date LV ejection fraction ( LVEF ) 3650 % document imaging ( preferably MRI echocardiographic method ) , within 12 calendar month consent date least 3 calendar month recent Myocardial Infarction ( MI ) , percutaneous coronary intervention ( PCI ) coronary artery bypass graft ( CABG ) . One clinically document , enzymepositive myocardial infarction , 3 calendar month prior consent date* . ( If enzyme information clinical documentation available , must clear evidence prior silent myocardial infarction identify either new pathologic Q wave ECG image documentation infarcted area ( left ventricular angiography/ nuclear scan/ MRI ) Note : MI qualification base Universal Definition MI ) Qualifying 12lead ECG within 6 calendar month consent date least 3 calendar month recent MI , PCI CABG . ( The qualifying ECG* sinus rhythm atrial fibrillation ( patient persistent permanent atrial fibrillation control ventricular response &lt; 100 bpm consent date ) *QRS duration qualify ECG &gt; 90 msec ) Passing SICD Screening ECG perform per applicable user 's manual consent date identifies one qualify SICD sense vector Ejection fraction &gt; 50 % &lt; 36 % within 12 calendar month prior consent date least 3 calendar month recent MI , PCI CABG Existing guideline base indication implantable cardioverter defibrillator ( ICD ) , pacemaker , cardiac resynchronization therapy device ( CRT ) , cardiac resynchronization therapy device defibrillator ( CRTD ) therapy Existing previously implant ICD , CRT , CRTD , pacemaker device system Active infection time consent Contraindication SICD implantation accord SICD pulse generator ( PG ) User 's Manual Hemodialysis and/or peritoneal dialysis time enrollment New York Heart Association Class IV past 3 calendar month prior time consent date Coronary artery bypass graft surgery percutaneous coronary intervention ( balloon and/or stent angioplasty ) within 3 calendar month prior consent date Enzymepositive myocardial infarction silent myocardial infarction diagnose within 3 calendar month prior consent date Unstable angina need outpatient treatment hospitalization ( change/addition antianginal medication and/or coronary revascularization ) , within 3 calendar month prior consent date Angiographic evidence coronary disease patient candidate coronary revascularization likely undergo CABG PCI next 3 calendar month High risk arterial embolism ( e.g . presence mobile leave ventricular thrombus ) Hemodynamically significant congenital heart disease , aortic valvular heart disease , amyloid heart disease Baseline body mass index &gt; 45 kg/m2 On heart transplant list likely undergo heart transplant within one calendar year Presence disease , subject 's cardiac disease , opinion investigator likely significantly reduce patient 's likelihood survival duration trial ( e.g . cancer , liver failure ) . Unwillingness inability cooperate protocol Resides distance enrol site travel followup visit would unusually difficult Reversible cause heart disease ( e.g . viral myocarditis tachycardia induce cardiomyopathy ) Participation clinical trial ( observational registry allow approval CDC ) Does anticipate reside vicinity enrol site duration trial Unwillingness sign consent participation</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Subcutaneous</keyword>
	<keyword>Implantable Cardioverter Defibrillator</keyword>
	<keyword>MADIT</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Myocardial Infarction</keyword>
</DOC>